Mubadala-backed Kelix Bio seals MENA insulin manufacturing deal

The undisclosed deal for DiabTec, struck with Jalphur, gives the firm a MENA manufacturing base, as Kelix Bio continues its acquisition spree.

Andrew Tjaardstra

January 16, 2025

Dubai-headquartered Kelix Bio, wholly owned by Abu Dhabi’s Mubadala Investment (Mubadala), has completed the acquisition of insulin manufacturer DiabTec, a subsidiary of Ras Al Khaimah-headquartered Julphar, for an undisclosed fee.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Companies
M&A
Rest Of World

#middle east
#acquisition